Important updates regarding NHF's 72nd Bleeding Disorders Conference.
Christi Humphrey, LCSW of Hemophilia of Georgia and Jhon Velasco, MA of NHF discuss the principles of anger and how it works in/through the body.
NHF has learned of the recent death of a patient who had been participating in a gene therapy clinical trial for a rare muscle disorder known as X-Linked Myotubular Myopathy.
Pending regulatory clearance, CSL Behring would acquire exclusive global license rights from uniQure to commercialize etranacogene dezaparvovec, otherwise known as AMT-061.
The factor product donation made by the two companies is in support of the World Federation of Hemophilia's Humanitarian Aid Program.
Healthcare providers who complete the activity will learn about the important role of log-keeping for the home treatment of hemophilia patients and much more.
This webinar will cover pain in the bleeding disorder community in the context of the COVID pandemic.
These activities are designed for clinical staff including nurses, social workers, physical therapists, pharmacists, and other multidisciplinary providers involved in the management of persons with hemophilia receiving care in the federally recognized U.S. HTC network.
Many of the charitable organizations you may be familiar also have COVID-19 specific funds.
The updated trial data from BioMarin have been submitted as a late-breaking abstract to the upcoming World Federation of Hemophilia (WFH) Virtual Summit to be held June 14-19, 2020.